Is doxycycline an appropriate first‑line therapy for pneumonic plague in an otherwise healthy adult?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Recommendation

No—do not use doxycycline as first-line for pneumonic plague; use a fluoroquinolone (ciprofloxacin, levofloxacin, or moxifloxacin) or an aminoglycoside (gentamicin or streptomycin), reserving doxycycline only as an alternative. 1

Evidence basis (prioritizing morbidity, mortality, QOL)

  • Guideline (CDC/US HHS 2021): For adults with pneumonic plague, first-line therapy is a fluoroquinolone (ciprofloxacin, levofloxacin, moxifloxacin) or an aminoglycoside (gentamicin, streptomycin); doxycycline is listed only as an alternative, with notes of reduced efficacy in pneumonic disease. Duration 10–14 days. Use dual therapy initially if severe disease or suspected engineered resistance; otherwise monotherapy is acceptable once improving 1.
  • Rationale and nuance:
    • Animal models show doxycycline is ineffective for pneumonic plague treatment compared with ciprofloxacin, supporting its non–first-line status for lung infection, which directly impacts mortality and QOL 2, 3.
    • Doxycycline is first-line for bubonic/pharyngeal plague, but that does not extend to pneumonic disease due to lower observed efficacy in lungs 1.
  • Drug label: Doxycycline is FDA-indicated for plague due to Yersinia pestis, but the label does not specify pneumonic as first-line; guideline positioning remains alternative for pneumonic disease to optimize survival 4.

Practical algorithm (adult, otherwise healthy)

  1. If suspected or confirmed pneumonic plague:
    • Start immediately with one of:
      • Ciprofloxacin 400 mg IV q8h or 750 mg PO q12h, or
      • Levofloxacin 750 mg IV/PO q24h, or
      • Moxifloxacin 400 mg IV/PO q24h, or
      • Gentamicin 5 mg/kg IV/IM q24h, or
      • Streptomycin 1 g IV/IM q12h
    • Choose fluoroquinolone if concomitant CAP coverage is needed; excellent lung penetration supports mortality benefit 1.
    • Severe disease or concern for engineered resistance: initiate dual therapy with two classes, then narrow when clinically improved 1.
    • Treat 10–14 days 1.
  2. Use doxycycline only if first-line agents are contraindicated/unavailable:
    • Doxycycline 200 mg loading dose, then 100 mg IV/PO q12h (10–14 days) 1.
  3. Reassess rapidly with susceptibility data; resistance is rare but possible—ensure prompt AST if clinical response is suboptimal 1, 5.

Pitfalls and caveats

  • Do not rely on doxycycline as initial monotherapy for pneumonic plague—animal data and guideline hierarchy indicate lower efficacy in lungs, risking higher mortality 1, 2, 3.
  • Delay in effective therapy (>24 hours from symptom onset) markedly worsens outcomes; start guideline-preferred agents immediately to reduce mortality 5.
  • If diagnosis uncertain, prefer levofloxacin or moxifloxacin to cover typical/atypical CAP pathogens while treating plague, improving QOL and survival 1.

Dosing summary (adult)

  • First-line:
    • Ciprofloxacin 400 mg IV q8h or 750 mg PO q12h; or
    • Levofloxacin 750 mg IV/PO q24h; or
    • Moxifloxacin 400 mg IV/PO q24h; or
    • Gentamicin 5 mg/kg IV/IM q24h; or
    • Streptomycin 1 g IV/IM q12h 1.
  • Alternative:
    • Doxycycline 200 mg load, then 100 mg IV/PO q12h 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.